

1      **Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in**  
2      **Human Lung Tissue Cells**

3

4      Judith Grau-Expósito<sup>1\*</sup>, David Perea<sup>1\*</sup>, Marina Suppi<sup>1</sup>, Núria Massana<sup>1</sup>, Ander Vergara<sup>2</sup>, Maria  
5      José Soler<sup>2</sup>, Benjamin Trinite<sup>3</sup>, Julià Blanco<sup>3,4</sup>, Javier García-Pérez<sup>5,6</sup>, José Alcami<sup>5,6,7</sup>, Anna  
6      Serrano-Mollar<sup>8,9</sup>, Joel Rosado<sup>10</sup>, Vicenç Falcó<sup>1</sup>, Meritxell Genescà<sup>1\*</sup>, and Maria J. Buzon<sup>1\*</sup>

7      <sup>1</sup>Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari  
8      Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. VHIR Task Force COVID-  
9      19.

10     <sup>2</sup>Nephrology Research Department, Vall d'Hebron Research Institute (VHIR), Hospital  
11     Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. VHIR Task  
12     Force COVID-19.

13     <sup>3</sup>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti  
14     Campus, Autonomous University of Barcelona (UAB), 08916 Badalona, Spain.

15     <sup>4</sup>Chair of Infectious Diseases and Immunity, University of Vic–Central University of Catalonia  
16     (UVic-UCC), 08500 Vic, Spain.

17     <sup>5</sup>AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III,  
18     Madrid, Spain.

19     <sup>6</sup>Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud  
20     Carlos III (ISCIII), Madrid, Spain

21     <sup>7</sup>Clinic HIV Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.

22     <sup>8</sup>Experimental Pathology Department, Institut d'Investigacions Biomèdiques de Barcelona,  
23     Consejo Superior de Investigaciones Científicas (IIBB-CSIC), Institut d'Investigacions  
24     Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

25     <sup>9</sup>Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES),  
26     Madrid, Spain.

27     <sup>10</sup>Thoracic Surgery and Lung Transplantation Department, Vall d'Hebron Institut de Recerca  
28     (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain. VHIR Task Force COVID-19.

29     **Running title:** Human lung for the study of SARS-CoV-2

30 **Corresponding authors\*:** Maria J. Buzon ([mariajose.buzon@vhir.org](mailto:mariajose.buzon@vhir.org)) and Meritxell Genescà


31 ([meritxell.genesca@vhir.org](mailto:meritxell.genesca@vhir.org))

32        **Abstract**

33        The development of physiological models that reproduce SARS-CoV-2 infection in primary  
34        human cells will be instrumental to identify host-pathogen interactions and potential  
35        therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we  
36        have developed a rapid platform for the identification of viral targets and the expression of viral  
37        entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory  
38        compounds. The direct use of HLT cells, without long-term cell culture and *in*  
39        *vitro* differentiation approaches, preserves main immune and structural cell populations,  
40        including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while  
41        maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147  
42        and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method,  
43        suitable for different SARS-CoV-2 variants, and provides the identification of new compounds  
44        missed by conventional systems, such as VeroE6. Using this method, we also show that  
45        interferons do not modulate ACE2 expression, and that stimulation of local inflammatory  
46        responses can be modulated by different compounds with antiviral activity. Overall, we present  
47        a relevant and rapid method for the study of SARS-CoV-2.

48

## Graphical Abstract



49

## 50 Highlights

51 *Ex vivo* physiological systems for the study of SARS-CoV-2-host interactions are scarce. Here, we  
52 establish a method using primary human lung tissue (HLT) cells for the rapid analysis of cell  
53 tropism and identification of therapeutics.

54

- 55 HLT cells preserve main cell subpopulations, including alveolar type-2 cells, and expression of SARS-CoV-2 entry factors ACE2, CD147, TMPRSS2 and AXL.
- 56 HLT cells are readily susceptible to SARS-CoV-2 infection without the need of cell isolation or further cell differentiation.
- 57
- 58 Antiviral testing in HLT cells allows the rapid identification of new drug candidates against SARS-CoV-2 variants, missed by conventional systems.
- 59

60           • Local inflammation is supported in HLT cells and offers the identification of relevant  
61           anti-inflammatory compounds for SARS-CoV-2 infection.

62        **Introduction**

63        Only one antiviral against SARS-CoV-2, remdesivir, has been approved for the treatment of  
64        COVID-19 in adults and pediatric patients (12 years of age and older) requiring hospitalization  
65        [1, 2]. Moreover, molnupiravir, a ribonucleoside analog that inhibits SARS-CoV-2 replication, has  
66        shown activity in several preclinical models of SARS-CoV-2, including prophylaxis, treatment, and  
67        prevention of transmission [3, 4]. Promising human clinical trials in non-hospitalized patients are  
68        ongoing (NCT04575597), and it could be the first oral antiviral medicine approved for COVID-19.  
69        Further, the development of *Acute Respiratory Distress Syndrome* in severe COVID-19 patients  
70        has been linked to dysregulated inflammatory responses. In this regard, treatment with the  
71        glucocorticoid dexamethasone decreased 28-day mortality among patients receiving invasive  
72        mechanical ventilation, but little benefit was observed in patients without respiratory support  
73        [5]. Despite these major advances in treatment options for COVID-19, the rapid identification of  
74        new antivirals that could be easily transferred into the clinic is still of paramount importance,  
75        particularly with the potential emergence of drug-resistant variants.

76        Screening of novel drug candidates is often performed using cell lines. In this sense, the most  
77        widely used cell lines for SARS-CoV-2 studies are epithelial cells derived either from lung (Calu-  
78        3), kidney (VeroE6), or colon (CaCo-2) [6]. These immortalized systems are highly reproducible  
79        and easy to handle but lack physiological relevance. The differential gene expression profiling of  
80        cell lines compared with primary cells from tissues might significantly affect important enzymes  
81        involved in the viral replication cycle. For instance, the level of ACE2 expression, the main  
82        receptor used by SARS-CoV-2 for viral entry, is variable among several cell lines [7], while only a  
83        small fraction of alveolar type II (AT-II) cells, the main target for SARS-CoV-2 in the distal lung,  
84        express ACE2 [8, 9]. In addition, SARS-CoV-2 spike (S) glycoprotein, which is responsible for viral  
85        entry into target cells, can be activated by several host proteases, such as furin, transmembrane  
86        serine proteinase 2 (TMPRSS2) and cathepsin L, in a pH-dependent or independent manner [10,  
87        11]. Whereas in some cell lines S protein is activated by endosomal pH-dependent protease  
88        cathepsin L, in airway epithelial cells viral entry depends on the pH-independent TMPRSS2  
89        protease [11]. Thus, it is currently not well defined if SARS-CoV-2 may utilize multiple cell-type-  
90        specific host proteins for viral replication in primary target tissues and therefore, the potency of  
91        therapeutics directed against these proteins may also differ.

92        Further, inflammatory immune responses might also impact viral dynamics in the lung by  
93        affecting the expression of entry receptors. In this sense, early studies discovered that ACE2 was  
94        a human interferon-stimulated gene (ISG); IFN- $\beta$  and IFN- $\gamma$  were shown to strongly upregulate

95 the expression of ACE2 at the mRNA and cell surface protein levels, indicating that inflammatory  
96 molecules could shape cell susceptibility to viral infection [12]. However, how anti-inflammatory  
97 drugs may affect ACE2 expression and facilitate SARS-CoV-2 infection remains to be elucidated.  
98 One study reported that the use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as  
99 ibuprofen, was linked to enhanced ACE2 expression in a diabetic-induced rat model [13] and  
100 other reports raised alarms regarding the possible role of NSAIDs at increasing susceptibility to  
101 SARS-CoV-2 infection [14, 15]. On the contrary, experimental and clinical evidence showed that  
102 medium-to-low-dose glucocorticoids may play a protective role in COVID-19 by activating ACE2  
103 and suppressing the associated cytokine storm [16]. Overall, the use of more relevant and  
104 physiological models for the study of SARS-CoV-2 infection, the identification of drug candidates,  
105 or the impact of new therapeutics on the disease, could significantly advance the successful  
106 translation of the results into the clinic.

107 Primary epithelial cell cultures of nasal and proximal airway epithelium have been used to study  
108 SARS-CoV-2 infection in the upper airways [9, 17-19]. Similarly, organ on-chip and organoid  
109 models of AT-II cells have been successfully developed [18, 20]. While very useful, these models  
110 require long-term culture (sometimes several weeks) combined with the addition of cytokines  
111 that might change cell functionality [21]. The direct use of human lung tissue (HLT) cells offers  
112 important advantages over other *in vitro* and *in vivo* approaches for several reasons; it mimics  
113 the main site of viral replication in the lung, contains all heterogeneous cell components present  
114 in the tissue (with greater functional complexity compared to cell lines), and the cells were not  
115 subjected to long-term culture nor exposed to *in vitro* differentiation approaches. In the past,  
116 similar lung models have been successfully established to study the effect of allergens and  
117 inflammatory stimuli [22, 23]. Importantly, using HLT cells allow mimicking an inflammatory  
118 local response that could be attenuated by anti-inflammatory drugs, providing a low/medium  
119 throughput screening of anti-inflammatory candidates for the treatment of airway diseases [24].  
120 Significantly, lung tissues not only can be infected with SARS-CoV-2, but also generate local  
121 immune responses to viral infection [25]. Considering all these factors, here we aimed to  
122 characterize a physiological human lung tissue system, which could be used for the study of  
123 virus-host interactions and the identification of potential antiviral compounds and their capacity  
124 to modify local inflammation.

125 **Results**

126 **Characterization of HLT cells**

127 Non-neoplastic lung parenchyma was obtained from hospitalized non-COVID19 patients  
128 undergoing thoracic surgery. First, we optimized cell culture and digestion conditions, since the  
129 methodology used for tissue processing can significantly impact cell-type yield, viability and  
130 function of target cell populations. We focused on the preservation of EpCAM<sup>+</sup> cells expressing  
131 HLA-DR [26, 27], which in adult alveolar parenchyma is characteristic of AT-II cells (thereafter  
132 referred as enriched AT-II cells). We also aimed to preserve several hematopoietic cell subsets,  
133 as shown in the flow cytometry gating strategy (**Figure S1A**). We observed that collagenase  
134 outperformed liberase and trypsin at preserving the enriched population of AT-II cells, the main  
135 SARS-CoV-2 target (**Figure S2A-B**). Among the hematopoietic cells present in lung parenchyma,  
136 we identified CD3 T lymphocytes (which represented  $7.39\% \pm 6.97$  out of the total living cells),  
137 myeloid dendritic cells ( $0.10\% \pm 0.06$ ), monocytes/macrophages subsets ( $1.36\% \pm 1.27$ ),  
138 neutrophils ( $5.00\% \pm 4.28$ ) and alveolar macrophages ( $0.21\% \pm 0.16$ ). Moreover, out of the non-  
139 hematopoietic cells (CD45-), enriched AT-II and endothelial cells represented  $1.11\% \pm 1.16$  and  
140  $0.78\% \pm 0.81$  of the total living cells, respectively. Based on EpCAM expression and lack of CD31  
141 and CD45, other epithelial cells including AT-I cells represented  $0.52\% \pm 0.46$  out of the living  
142 fraction (**Figure 1A**). All these populations have been previously identified in human lungs [25,  
143 28, 29]. Of note, other abundant structural cell subsets were not defined by specific phenotypic  
144 markers within the same panel. Moreover, the nature of AT-II cells in lung cell suspensions was  
145 also addressed by staining with phosphatase alkaline (**Figure 1B**), which is expressed in AT-II cells  
146 both *in vitro* and *in vivo* [30], and by detection of Surfactant Protein C, which is expressed  
147 exclusively by fully differentiated AT-II cells [31, 32] (**Supplementary Figure 1B**).

148 Next, we focus on the expression of previously identified proteins involved in viral entry.  
149 Single-cell transcriptome studies have shown that ACE2, one of the main host cell surface  
150 receptors for SARS-CoV-2 attachment and infection, is predominantly expressed by AT-II cells [9,  
151 33]. Moreover, ACE2 expression wanes in distal bronchiolar and alveolar regions paralleled by  
152 SARS-CoV-2 infectivity [9]. In human lung parenchyma-derived cells, we found ACE2 expression  
153 mainly associated to the population enriched in AT-II cells (**Figure 1C**), a finding that was  
154 confirmed by immunohistochemistry in concomitant tissue samples (**Figure 1D**). The percentage  
155 of cells expressing ACE2 was rather small and varied between individuals ( $6.23\% \pm 3.47$ ) (**Figure**  
156 **1C**), as previously described [8]. We also studied the expression of CD147, which has been  
157 reported as a route of SARS-CoV-2 infection *in vitro* and *in vivo* models [34]. CD147 was

158      ubiquitously expressed in several hematopoietic and non-hematopoietic cells (**Figure 1C**).  
159      Importantly,  $92.3\% \pm 2.4$  of the population enriched in AT-II cells expressed CD147 (**Figure 1C**).  
160      Similarly, and in agreement with other studies [35, 36], TMPRSS2 protease expression was also  
161      identified in several subsets, including enriched AT-II cells ( $31.08\% \pm 7.06$ ) (**Figure 1C**). When we  
162      studied the double expression of ACE2 and TMPRSS2, or ACE2 and CD147, we found that only  
163       $1.31\% \pm 0.70$  and  $3.02\% \pm 1.84$  of AT-II cells expressed both markers, respectively  
164      (**Supplementary Figure 3B**). Last, we studied the expression of AXL, another candidate receptor  
165      for SARS-CoV-2 entry in lung cells [37]. We detected high expression of AXL on myeloid dendritic  
166      cells ( $45.27\% \pm 17.11$ ), while only a fraction of the enriched AT-II cells (mean of  $3.82\% \pm 4.71$ )  
167      expressed AXL (**Supplementary Figure 3A**). Overall, we found that human lung cell suspensions  
168      preserved critical populations and factors required for SARS-CoV-2 infection.

169      **Susceptibility of HLT cells to SARS-CoV-2 viral entry**

170      Next, we assessed if HLT cells were susceptible to viral infection. We generated pseudotyped  
171      vesicular stomatitis virus (VSV) viral particles bearing the D614G form of the S protein of SARS-  
172      CoV-2 and expressing either luciferase (VSV\*ΔG (Luc)-S) or GFP (VSV\*ΔG (GFP)-S) reporter genes  
173      upon cell entry. As a control, we used the VSV-G virus, which has very broad cell tropism. As  
174      expected, VeroE6 cells were highly susceptible to SARS-CoV-2 entry, as demonstrated for  
175      VSV\*ΔG (GFP)-S and VSV-ΔG (Luc)-S (**Figure 2A**). Of note, camostat, an inhibitor of the host  
176      protease TMPRSS2, did not inhibit cell entry in this cell line, consistent with its lack of expression  
177      of this protein (**Figure 2B**). Anti-ACE2 antibody blocked more than 90% of VSV\*ΔG (Luc)-S, yet  
178      was inactive for VSV-G (Luc) infection (**Figure 2B**). This observation has been widely reported  
179      before [11, 38, 39], and identifies ACE2 as the main cell receptor required for viral entry in  
180      VeroE6. Importantly for viral pathogenesis, it has been postulated that SARS-CoV-2 S protein  
181      might downregulate ACE2 expression, as previously observed for SARS-CoV [40]. We  
182      consistently observed a significant strong reduction in ACE2 expression after viral entry (**Figure**  
183      **2C**).

184      We then evaluated the susceptibility of HLT cells to viral entry, using the same viral  
185      constructs. HLT cells were readily infected with pseudotyped S particles (VSV\*ΔG (Luc)-S and  
186      VSV\*ΔG (GFP)-S), with the natural donor variation representative of primary samples (**Figure**  
187      **2D**). As expected [9], lung cells enriched with the AT-II phenotype were identified as the main  
188      SARS-CoV-2 cell targets in steady conditions (**Figure 2E**). Blockade of ACE2 resulted in a donor-  
189      dependent reduction of viral infectivity, ranging from 50 to 100% (**Figure 2F**). Camostat  
190      significantly inhibited viral entry in all HLT assays, although the entry process was not always

191 completely abrogated (**Figure 2F**), suggesting that AT-II cells may become infected through the  
192 use of alternative factors [41]. Similarly, the presence of an anti-CD147 antibody and the  
193 recombinant protein AXL inhibited SARS-CoV-2 entry (**Figure 2F and Supplementary Figure 3D**).  
194 Collectively, these data indicate that HLT cells are susceptible to SARS-CoV-2 viral entry, and that  
195 ACE2, CD147, TMPRSS2 and AXL are important proteins required for viral entry in human lung  
196 cells. Thus, these results support the value of the direct use of HLT cells to successfully study  
197 SARS-CoV-2 viral entry, and related mechanisms, in a more physiological system compared to  
198 immortalized cell lines.

199 **Antiviral assays in HLT cells**

200 To validate the HLT system as a platform for the rapid screening of antiviral candidates, we  
201 assayed potential antiviral compounds, most of them previously identified by computational  
202 methods with predicted ability to inhibit SARS-CoV-2 cell entry due to their interaction with S  
203 protein or with the interface S-ACE2 [42]. A detailed description of the 39 selected drugs is  
204 available in **Table S1**. HLT cells were exposed to VSV\*ΔG (Luc)-S virus in the presence of 1/5  
205 serial dilution of the different tested compounds. 20h post-exposure, antiviral activity and cell  
206 viability were measured by luminescence. Cell viability for the individual HLT populations, before  
207 and after SARS-CoV-2 infection, was measured by flow cytometry and is shown in  
208 **Supplementary Figure 3C**. Antiviral results in HLT cells were systematically compared with  
209 parallel testing in the cell line VeroE6. Among the 39 drugs that were evaluated in our study, 15  
210 of them (38%) showed some antiviral activity against SARS-CoV-2 with EC<sub>50</sub> values ranging from  
211 0.37μM to 90μM (**Table S2**). From these, 25% had concordant results between both models  
212 (**Figure 3**). Cepharanthine, a naturally occurring alkaloid reported to have potent anti-  
213 inflammatory and antiviral properties, was one of the most potent antivirals identified in both  
214 systems, with EC<sub>50</sub> of 0.46μM and 6.08μM in VeroE6 and HLT cells, respectively (**Figure 3A and**  
215 **B**). Of note, we observed cell toxicity at the highest concentrations (CC<sub>50</sub><sub>VeroE6</sub>= 22.3μM; CC<sub>50</sub><sub>HLT</sub>=  
216 13.8μM), which translated in satisfactory *selectivity indexes* (SI= CC<sub>50</sub>/EC<sub>50</sub> of SI<sub>VeroE6</sub>= 48.47 and  
217 SI<sub>HLT</sub>= 2.64 [43]. The anti-SARS-CoV-2 activity of hydroxychloroquine, a compound known to  
218 interfere with endosomal acidification, which is necessary for cathepsin activity, has been  
219 extensively reported [44, 45]. In our study, we observed that hydroxychloroquine was equally  
220 effective at inhibiting viral entry in VeroE6 and HLT cells (EC<sub>50</sub><sub>VeroE6</sub>= 1.58μM; EC<sub>50</sub><sub>HLT</sub>= 3.22μM)  
221 (**Figure 3A, B**), with no apparent cytotoxicity (**Figure 3C**). Ergoloid, an approved drug used for  
222 dementia, and recently identified as a potential inhibitor of main protease of SARS-CoV-2 [46],  
223 induced ~90% of viral entry inhibition in HLT cells at non-toxic concentrations (**Figure 3A-C**).  
224 Indeed, SI for this compound was higher in the HLT model than in VeroE6 cells (SI<sub>VeroE6</sub>= 3.9; SI<sub>HLT</sub>

225 = 11.38). Similarly, ivermectin, a broad-spectrum anti-parasitic compound, showed very similar  
226 antiviral potency in both models, however  $SI$  greatly differed between them ( $SI_{VeroE6} = 1.4$ ;  $SI_{HLT} =$   
227 7.75). Additionally, we plot the individual  $EC_{50}$  values obtained from the different donors. We  
228 show that the assay was reproducible (**Supplementary Figure 3E**), highlighting the suitability of  
229 the HLT system for the rapid identification of antivirals.

230 We also detected discordant antiviral results between both models (**Figure 4**). Four drugs  
231 inhibited SARS-CoV-2 entry in HLT cells without affecting cell viability, with no antiviral effect in  
232 VeroE6 (**Figure 4A-C**). As expected and mentioned before, camostat, a TMPRSS2 inhibitor [47],  
233 was not active in VeroE6 cells due to the lack of TMPRSS2 expression in this cell line. However,  
234 camostat was highly active in HLT cells ( $EC_{50}=3.3\mu M$ ). However, in a clinical trial with Covid-19  
235 patients receiving camostat within the first 48h of admission, no significant benefit was  
236 observed [48]. Yet, the potential benefit of camostat during the early phase of infection remains  
237 to be addressed. Further, valaciclovir, an antiviral drug, presented some inhibitory potential at  
238 100  $\mu M$  only in HLT cells. Interestingly, phenformin, an antidiabetic drug and an mTOR inhibitor,  
239 has been postulated as an inhaled drug candidate against influenza and coronavirus infections  
240 [49]. Phenformin reduced the incidence of influenza infection in diabetic patients during the  
241 1971 outbreak [49]. Here, we detected that phenformin significantly reduced viral entry at 20-  
242 100  $\mu M$  only in HLT cells, supporting previous recommendations as inhaled treatment. Finally,  
243 eriodictyol, a flavonoid used as a medicinal plant [50], demonstrated certain activity starting at  
244 4  $\mu M$ . In contrast, quercetin induced some viral entry suppression only in VeroE6 cells and at  
245 high concentrations (**Figure 4A-C**). To further demonstrate the suitability of our model to test  
246 antivirals against other SARS-CoV-2 variants, we tested the inhibitory capacity of the drugs with  
247 the lowest  $IC_{50}$  values, cepharnthine, camostat, ivermectin, hydroxychloroquine, and  
248 ciclesonide using a pseudovirus containing the SARS-CoV-2 spike of the delta variant. Similar  
249 inhibitory dynamics for all tested drugs were shown using both viral variants, indicating the  
250 versatility of our model (**Figure 4D**).

251 Last, we verified our main findings in HLT cells using a replication-competent SARS-CoV-2  
252 virus. Although we initially also included ergoloid, we observed high toxicity in HLT cells (>60%  
253 cell toxicity) at longer incubation times (48h), which precluded the execution of the antiviral  
254 assay (**Supplementary Figure 3F**). HLT cells were infected with a SARS-CoV-2 clinical isolate and  
255 viral genomes were measured in the supernatant of cell cultures by RT-PCR in the presence of  
256 the different drugs. SARS-CoV-2 successfully replicated in HLT samples (**Figure 4E**), and viral  
257 replication was partially inhibited by all five drugs (**Figure 4F**). These results are consistent with  
258 previous reports describing the antiviral potency of camostat using precision-cut lung slices from

259 donors [47, 51]. Overall, these results indicate that HLT cells represent a reproducible and  
260 relevant system for the screening of antivirals in a physiological model. This system not only  
261 recapitulates the main antiviral activities observed in cell models, but also allows the  
262 identification of new compounds missed by conventional systems.

263 **Impact of inflammation and anti-inflammatory drugs on ACE2 expression and SARS-CoV-2**  
264 **viral entry**

265 Since SARS-CoV-2 viral infection rapidly induces an inflammatory response, we wondered if  
266 certain components of this response could modulate ACE2 expression, potentially increasing  
267 viral binding of SARS-CoV-2 and thus, enhancing infection. Further, ACE2 has been previously  
268 identified as an ISG or a component of the IFN-signaling pathway [12, 52], and a recent  
269 investigation showed that cultured human primary basal epithelial cells treated with IFN- $\alpha$ 2 and  
270 IFN- $\gamma$  led to upregulation of ACE2 [12]. Moreover, IL-1 $\beta$  and IFN- $\beta$  upregulated ACE2 in large  
271 airway epithelial cell cultures [9]. Thus, considering that type I interferons represent a first line  
272 of defence against viral infections and that several cytokines are rapidly induced and associated  
273 with disease severity in COVID-19 patients [53], we tested the effects of different molecules on  
274 ACE2 expression in HLT cells. In initial experiments, we tested three different doses of a wider  
275 range of molecules (including tumor necrosis factor (TNF), IL-6 and IFN- $\gamma$  that were subsequently  
276 discarded), which were used to select doses and compounds of interest. Finally, the effect of  
277 IFN- $\alpha$ 2, IFN- $\beta$ 1, IL-1 $\beta$ , IL-10 and GM-CSF on ACE2 expression was evaluated in HLT cells. Cells  
278 were then treated with selected immune stimuli and cultured for 20h, when the expression of  
279 ACE2 in enriched AT-II cells was evaluated by flow cytometry. The only significant change we  
280 observed was for IL-1 $\beta$  stimulation, which decreased the fraction of AT-II cells expressing ACE2  
281 (**Figure 5A**). No other significant changes were observed, indicating that relevant inflammatory  
282 stimuli, besides IL-1 $\beta$ , have a limited impact on ACE2 expression in AT-II cells.

283 Moreover, it is currently not well documented if anti-inflammatory drugs could modulate  
284 ACE2 expression, and consequently, impact susceptibility to SARS-CoV-2 infection [54]. Several  
285 glucocorticoids have shown to impart activating effects on ACE2 expression in cell lines; cortisol  
286 showed the strongest effect on ACE2 activation, followed by prednisolone, dexamethasone, and  
287 methylprednisolone [16]. Moreover, NSAIDs, compounds that inhibit cyclooxygenase-1 and 2  
288 mediating the production of prostaglandins, which play a role in inflammatory responses, have  
289 been linked to ACE2 upregulation [16]. Here, we use HLT cells to study the effect of several anti-  
290 inflammatory drugs on both ACE2 expression and SARS-CoV-2 viral entry. 1/5 dilutions of  
291 ibuprofen, cortisol, dexamethasone and prednisone were added to HLT cells for 20h. Overall, no

292 effect on ACE2 expression was observed after the addition of these anti-inflammatory drugs  
293 (**Figure 5B**). Consequently, tested anti-inflammatory compounds showed no major impact of the  
294 viral entry assay; however, high concentrations of prednisone and dexamethasone showed a  
295 partial reduction of viral entry in HLT cells, without any apparent impact on VeroE6 cells (**Figure**  
296 **5C**). Thus, selected anti-inflammatory drugs had limited impact on ACE2 expression within  
297 enriched AT-II cells from the HLT model, as well as in SARS-CoV-2 viral entry.

298 **Anti-inflammatory properties of selected compounds**

299 Last, we were interested in modelling the anti-inflammatory properties of several drugs in  
300 HLT cells. Based on their previous antiviral potency, we selected cepharamthine, ergoloid,  
301 camostat, ivermectin, hydroxychloroquine and ciclesonide for further evaluation. Of note, some  
302 of these drugs have been previously identified as immunomodulators with anti-inflammatory  
303 effects (**Table S1**). However, their direct impact on inflammatory molecules directly secreted by  
304 human lung cells have not been evaluated. HLT cells were stimulated with lipopolysaccharides  
305 (LPS) and IFN- $\gamma$  in the presence of these antivirals and, 20h after, the expression of IL-6 and  
306 CXCL10, a potent pro-inflammatory cytokine and a chemokine respectively, were intracellularly  
307 measured by flow cytometry. IL-6 and CXCL10 were selected as molecules significantly increased  
308 in severe patients during acute infection, with a prediction value for hospitalization [55]. A  
309 representative flow cytometry gating strategy is shown in **Figure S4**. As shown in **Figure 6A**, two  
310 major subpopulations of myeloid cells contributed to the upregulation of CXCL10 and IL-6  
311 expression upon stimulation. Myeloid CD11b $^+$ CD14 $^+$  were the cells with a greater response, with  
312 50% of these cells expressing IL-6 and 30% expressing CXCL10 after stimulation (**Figure 6B**).  
313 Using this model of local inflammation, we tested the capacity of the selected compounds to  
314 attenuate this response. We observed that camostat had the most potent effect, which  
315 significantly reduced the expression of CXCL10 in CD11b $^+$ CD14 $^-$  and of IL-6 in CD11b $^+$ CD14 $^+$   
316 myeloid subsets (**Figure 6B**). Ergoloid, which has not been linked to modulation of inflammation  
317 before, significantly reduced the expression of cytokines in CD11b $^+$ CD14 $^+$  myeloid cells, and  
318 cepharamthine reduced IL-6 production within this same subset. In contrast, ciclesonide induced  
319 CXCL10 secretion in CD11b $^+$ CD14 $^-$  myeloid cells (**Figure 6B**). Altogether, our results validate the  
320 use of HLT cells as a relevant method for the identification of anti-inflammatory compounds  
321 impacting specific pro-inflammatory cell populations located in the lung parenchyma.

322      **Discussion**

323      The emergency created by the fast spread of SARS-CoV-2 infection worldwide required a  
324      quick response from physicians treating these patients, who adapted to the rapid knowledge  
325      being generated by both clinical practice and basic research. However, up to date, only one  
326      antiviral drug against SARS-CoV-2 has been approved for clinical use. New antivirals are urgently  
327      needed, and the choice of the cell and animal models used to test the efficacy of drugs will  
328      impact its rapid translation into the clinics. Here, we propose the use of human lung tissue (HLT)  
329      cells as a method that can be safely performed in a BSL2 facility, which allows i) the identification  
330      of cell targets and expression of viral entry factors, ii) the impact of inflammation on host-  
331      pathogen interactions and iii) a rapid medium-high throughput drug screening of entry inhibitors  
332      against SARS-CoV-2 variants and local anti-inflammatory candidates.

333      Using pseudotyped viral particles expressing the SARS-CoV-2 spike, we first corroborated that  
334      a fraction of CD45<sup>-</sup> CD31<sup>-</sup> HLA-DR<sup>+</sup> and EpCam<sup>+</sup> is enriched in AT-II cells and are the primary cell  
335      target in lung tissue in steady conditions. This agrees with several studies using different  
336      approximations [12, 36, 56] and validates our primary model for viral tropism identification.  
337      While cell lines have been traditionally used for the screening of potential antiviral compounds  
338      due to their reproducibility, as well as being quick and user-friendly assays, they lack  
339      physiological relevance. Similarly, entry receptors and viral factors have been identified using  
340      immortalized cell lines [11, 57], and cell targets for SARS-CoV-2 in tissues have been mainly  
341      determined by analyzing the expression of viral entry factors in RNA-seq datasets [58] or using  
342      replication-competent SARS-CoV-2 isolates in BSL3 facilities [59]. Importantly, these studies  
343      have identified AT-II cells as main viral targets for SARS-CoV-2 infection in the lungs, and the  
344      molecules ACE2, CD147, TMPRSS2 and AXL as important factors for viral entry [11, 34, 37, 60].  
345      However, the development of more refined and translational *ex vivo* models of SARS-CoV-2  
346      entry will not only have implications for understanding viral pathogenesis, but also will be useful  
347      for the characterization of cell targets under specific conditions or for the identification of  
348      potential antivirals blocking viral entry in primary cells. The direct use of HLT cells allows the  
349      maintenance of cell type diversity and it may represent a significant advantage over previous  
350      models [18, 20, 61].

351      Moreover, we showed that the HLT cells can be successfully used for drug screening  
352      purposes, not only against the D614G virus but also against the delta variant. We tested 39 drugs  
353      and compared the results with antiviral testing in VeroE6 cells. Not surprisingly, we showed  
354      discordant results between both methods. Indeed, we found that 33.3% of the tested

355 compounds had discordant results between HLT and VeroE6 cells; 26.66% of drugs showed some  
356 antiviral effect in HLT but no activity was detected in VeroE6, and 6.67% showed only antiviral  
357 effects in VeroE6 cells. Among other reasons, the differential expression of several key proteins  
358 needed for viral entry, might explain current discrepancies between cell types. Importantly,  
359 using HLT cells, we identified several compounds with antiviral activity; cepharanthine showed  
360 an EC<sub>50</sub> of 6.08μM and concordantly, it was recently identified in a high throughput screening as  
361 one of the most potent drugs against SARS-CoV-2 [62], likewise several other studies have  
362 pointed towards this drug as a potent entry and post-entry SARS-CoV-2 inhibitor [63]. Instead,  
363 for hydroxychloroquine, an early report suggested no antiviral activity in human lung cells due  
364 to different expression of the required proteases for viral entry [64]. Furthermore, clinical trials  
365 failed to show effectiveness of this drug as a treatment for COVID-19 [65-67]. A strong  
366 dependency of SARS-CoV-2 on TMPRSS2 for viral entry, rather than on cathepsin L, was  
367 identified as a possible mechanistic explanation for its failure *in vivo* [68]. In our study, however,  
368 we observed that this drug was equally effective at inhibiting viral entry in VeroE6 and HLT cells,  
369 and also was effective when using replication competent viral isolates in HLT cells. Concordantly,  
370 in differentiated air-liquid interface cultures of proximal airway epithelium and 3D organoid  
371 cultures of alveolar epithelium, hydroxychloroquine significantly reduced viral replication [69].  
372 The multiple mechanisms of action postulated for hydroxychloroquine action, including  
373 interference in the endocytic pathway, blockade of sialic acid receptors and restriction of pH  
374 mediated S protein cleavage at the ACE2 binding site [70], could help to explain its antiviral effect  
375 in primary lung cells. Similarly, we identified ivermectin as an effective antiviral in HLT cells. Of  
376 note, ivermectin received limited attention as a potential drug to be repurposed against COVID-  
377 19 based on its limited ability to reach lung tissue *in vivo* [71]. Further, a clinical trial failed to  
378 show a reduction in the proportion of PCR-positive patients seven days after ivermectin  
379 treatment [72].

380 Importantly, HLT cells also provide a platform for testing anti-inflammatory drugs and the  
381 modulation of viral entry factors with drug candidates and immunomodulatory stimuli. We  
382 showed that IL-1β was able to reduce ACE2 expression in the fraction of enriched AT-II cells, in  
383 contrast to other cytokines induced during SARS-CoV-2 infection like IFN-α2, IFN-β1, IL-10 and  
384 GM-CSF, which did not impact ACE2 protein production. In primary epithelial cells derived from  
385 healthy nasal mucosa, Ziegler et al. [12] showed a significant induction of ACE2 transcripts after  
386 IFN-α2 and IFN-γ stimulation, as well as and in a human bronchial cell line treated with either  
387 type I or type II IFN. Moreover, the authors showed that influenza A virus infection  
388 increased ACE2 expression in lung resections [12], strongly suggesting that ACE2 was an

389 ISG. However, following studies showed that ACE2 transcription and protein production was not  
390 responsive to IFN. Instead, they described a new RNA isoform, MIRb-ACE2, that was highly  
391 responsive to IFN stimulation, but importantly, encoded a truncated and unstable protein  
392 product [73, 74]. These results highlight the need to validate scRNA-seq data with orthogonal  
393 approaches, such as the confirmation of protein expression levels in relevant systems. In HLT  
394 cells, we quantified ACE2 protein expression and importantly, focused our analysis on putative  
395 AT-II cells, the main SARS-CoV-2 targets in lung parenchyma. Also, in agreement with our results,  
396 a primary human bronchial epithelial cell model, type I ( $\beta$ ), II ( $\gamma$ ), or III ( $\lambda 1$ ) IFNs did not induce  
397 ACE2 expression [75]. Moreover, a study performed by Lang et al [76], showed that IFN- $\gamma$  and  
398 IL-4 downregulate the SARS-CoV receptor ACE2 in VeroE6 cells, and similarly, stimulation of  
399 A549 cells with IFN- $\alpha$ , IFN- $\gamma$ , and IFN- $\alpha$ +IFN- $\gamma$  did not identify ACE2 as an ISG [77].

400 A feasible explanation for the decrease of ACE2 protein production upon IL-1  $\beta$  treatment is  
401 that IL-1 $\beta$  activates disintegrin and metalloproteinase domain-containing protein 17 (ADAM17)  
402 [78], which mediates the shedding of ACE2 [79]. Although this effect would seem positive to  
403 reduce SARS-CoV-2 infection, ACE2 is a lung-protective factor, as it converts Angiotensin (Ang)  
404 II to Ang-(1-7); while Ang II promotes harmful effects in the lung, e. g. fibrosis, vasoconstriction,  
405 inflammation, endothelial dysfunction, edema, and neutrophil accumulation[80], Ang-(1-7) has  
406 counter-regulatory effects protective of lung injury. Moreover, Ang-(1-7) plays an essential role  
407 in hemostasis, as it favors anti-thrombotic activity in platelets [81]. In any case, treatment of  
408 COVID-19 patients with respiratory insufficiency and hyper inflammation with IL-1 inhibitors was  
409 associated with a significant reduction of mortality [82], indicating that at least during severe  
410 COVID-19 the overall effect of IL-1 $\beta$  is detrimental. While the reduction of ACE2 expression in  
411 AT-II cells by IL-1 $\beta$  may be of interest, it needs to be determined if in combination with other  
412 cytokines rapidly induced during viral respiratory infection [83], this effect would remain.  
413 Further, glucocorticoids and NSAIDS have been linked to ACE2 upregulation previously [16]. In  
414 contrast, we did not observe any significant impact of ibuprofen, cortisol, dexamethasone and  
415 prednisone on ACE2 protein expression. These results are concordant with a recent report  
416 showing that suppression of cyclooxygenase (COX)-2 by two commonly used NSAIDs, ibuprofen  
417 and meloxicam, had no effect on ACE2 expression, viral entry, or viral replication in a mouse  
418 model of SARS-CoV-2 infection [84]. Moreover, dexamethasone incompletely reduced viral  
419 entry. This observation partially agrees with a study using lung cells previously treated with  
420 dexamethasone, which showed significant suppression of SARS-CoV-2 viral growth [25].

421 We additionally show the interest of the HLT model to test local inflammation and evaluate  
422 potential anti-inflammatory drugs. The culture of diverse cell subsets localized in the lung

423 parenchyma, without further cell separation, allows the detection of inflammatory responses  
424 generated by different resident subpopulations, which is a significant advantage over  
425 monoculture. Several resident-myeloid subsets, together with newly recruited ones, may  
426 contribute to the rapid cytokine storm detected in COVID-19 patients [85-87]. Thus, the  
427 identification of antiviral drugs that can also limit the extent of these initial pro-inflammatory  
428 events may offer added value to the overall therapeutic effect of a given drug. In this sense, we  
429 observed that camostat significantly reduced the expression of proinflammatory molecules IL-6  
430 and CXCL10 in several myeloid CD11b<sup>+</sup> subsets. Concordantly, in a previous study using primary  
431 cultures of human tracheal epithelial cells infected with H1N1 virus, camostat also reduced the  
432 concentrations of the cytokines IL-6 and TNF in cell supernatants [88], suggesting a potent anti-  
433 inflammatory potential. In contrast, ivermectin did not affect the expression of cytokines in our  
434 model. However, ivermectin was previously shown to have protective anti-inflammatory effects  
435 in mice, reducing the production of TNF, IL-1 and IL-6 *in vivo* and *in vitro* [89]. Of note, in our  
436 system we optimized the detection of changes for the intracellular expression of IL-6 and CXCL10  
437 by local myeloid cells, and thus, how these intracellular changes reflect total production in  
438 supernatant needs further evaluation.

439 Finally, it is also important to note the potential limitations of the model. First, we did not  
440 maintain the cells in an air-liquid interface, which may alter cell function. Other limitations  
441 include the limited availability of human lung samples, inter-patient variation (age, smoking,  
442 etc.), the effects on lung biology of the medical condition instigating surgery, and the exact  
443 location of the sample resection, which may affect the proportion of cell subsets such as AT-II.  
444 However, this variability is what shapes the HLT into a more physiological and relevant model in  
445 comparison to current methods based on immortalized cell cultures. Besides the interest of the  
446 different readouts from HLT cell-based system as proposed here, our results highlight drugs with  
447 antiviral activity together with immunomodulatory properties, which could increase the benefit  
448 of a given treatment during COVID-19 disease progression. For instance, camostat,  
449 cepharanthine and ergoloid were three of the most potent drugs inhibiting SARS-CoV-2 entry,  
450 and remarkably, also exerted a significant anti-inflammatory effect on myeloid cells. Clinical  
451 trials with camostat, ergoloid and cepharanthine, ideally administrated during early infection,  
452 should shed light on their use as both antivirals and anti-inflammatory compounds.

453 **Materials and methods**

454 **Cells and virus**

455 VeroE6, isolated from kidney epithelial cells of an African green monkey, were grown in  
456 DMEM medium supplemented with 10% fetal bovine serum (FBS; Gibco) 100 U/ml penicillin,  
457 and 100 µg/ml streptomycin (Capricorn Scientific) (D10) and maintained at 37°C in a 5% CO<sub>2</sub>  
458 incubator.

459 The spike of the SARS-CoV-2 virus (D614G variant) was generated (GeneArt Gene Synthesis,  
460 ThermoFisher Scientific) from the codon-optimized sequence obtained by Ou et al. [41] and  
461 inserted into pcDNA3.1D/V5-His-TOPO (pcDNA3.1-S-CoV2Δ19-G614). The spike of the SARS-  
462 CoV-2.SctΔ19 B.1.617.2 (delta) virus was generated (GeneArt Gene Synthesis, ThermoFisher  
463 Scientific) from the full protein sequence of the original SARS-CoV-2 isolate Wuhan-Hu-1 (WH1)  
464 modified to include the mutations specific to the delta variant (VOC-21APR-02: T19R, 157-  
465 158del, L452R, T478K, D614G, P681R, D950N). These plasmids present the mutation D614G and  
466 a deletion in the last 19 amino acids from the original spike. Pseudotyped viral stocks of  
467 VSV\*ΔG(Luc)-S were generated following the protocol described by Whitt [90] with some  
468 modifications. Briefly, 293T cells were transfected with 3µg of the plasmid encoding the SARS-  
469 CoV-2 spike. Next day, cells were infected with a VSV-G-Luc virus (MOI=1) (generated from a  
470 lentiviral backbone plasmid that uses a VSV promoter to express luciferase) for 2h and gently  
471 washed with PBS. Cells were incubated overnight in D10 supplemented with 10% of I1  
472 hybridoma (anti-VSV-G) supernatant (ATCC CRL-2700) to neutralize contaminating  
473 VSV\*ΔG(Luc)-G particles. Next day, the resulting viral particles were collected and titrated in  
474 VeroE6 cells by enzyme luminescence assay (Britelite plus kit; PerkinElmer), as described  
475 previously [91].

476 **Lung tissue**

477 Lung tissues were obtained from patients without previous COVID-19 history and a recent  
478 negative PCR test for SARS-CoV-2 infection undergoing thoracic surgical resection at the  
479 Thoracic Surgery Service of the Vall d'Hebron University Hospital. Study protocol was approved  
480 by the Ethical Committee (Institutional Review Board number PR(AG)212/2020). Non-neoplastic  
481 tissue areas were collected in antibiotic-containing RPMI 1640 and immediately dissected into  
482 approximately 8-mm<sup>3</sup> blocks. These blocks were first enzymatically digested with 5 mg/ml  
483 collagenase IV (Gibco) and 100 µg/ml of DNase I (Roche) for 30 min at 37°C and 400 rpm and,  
484 then, mechanically digested with a pestle. The resulting cellular suspension was filtered through

485 a 70 $\mu$ m-pore size cell strainer (Labclinics) and washed twice with PBS. Pellet recovered after  
486 centrifugation was resuspended in fresh medium (RPMI 1640 supplemented with 5% FBS, 100  
487 U/ml penicillin, and 100  $\mu$ g/ml streptomycin) and DNase I to dissolve cell aggregates, and the  
488 resulting cell suspension was then filtered through a 40 $\mu$ m-pore size cell strainer (Labclinics).  
489 Cell number and viability were assessed with LUNA™ Automated Cell Counter (Logos  
490 Biosystems). For cell phenotyping the following antibodies were used: anti-CD31 (PerCP-Cy5.5,  
491 BioLegend), anti-CD11b (FITC, BioLegend), anti-CD11c (Pe-Cy7, BD Biosciences), anti-E-cadherin  
492 (Pe-CF594, BD Biosciences), primary goat anti-ACE2 (R&D systems), anti-CD14 (APC-H7, BD  
493 Biosciences), anti-CD45 (AF700, BioLegend), anti-EpCAM (APC, BioLegend), anti-CD3 (BV650, BD  
494 Biosciences), anti-CD15 (BV605, BD Biosciences) and anti-HLA-DR (BV421, BioLegend). For ACE2  
495 detection, after surface staining, cells were stained with secondary donkey anti-goat IgG (PE,  
496 R&D Systems) for 30 min at 4 °C. Cell viability was determined using an AQUA viability dye for  
497 flow cytometry (LIVE/DEAD fixable AQUA, Invitrogen). In some experiments, instead of CD11b  
498 or CD15, we used a primary rabbit anti-TMPRSS2 or anti-CD147 (BV605, BD Biosciences),  
499 respectively. For TMPRSS2 detection, after ACE2 staining with the appropriate secondary  
500 antibody, cells were washed twice with PBS 1% NMS (normal mouse serum) and then stained  
501 with a secondary goat anti-rabbit IgG (AF488, Thermofisher) for 30 min at 4°C. For SPC detection,  
502 after surface staining with a primary rabbit anti-SPC antibody (Biorbyt) and instead of ACE2  
503 staining, cells were stained with a secondary donkey anti-rabbit IgG (PE, Biolegend) for 30 min  
504 at 4 °C. After fixation with PBS 2% PFA, cells were acquired in an LSR Fortessa (BD Biosciences),  
505 and data were analyzed using the FlowJo v10.6.1 software (TreeStar).

506 **Cytospin and alkaline phosphatase staining**

507 Cytospin preparations were obtained from freshly isolated human lung cells at an  
508 approximate density of 150,000 cells/slide, and air-dried during 15 min. Cells were stained with  
509 alkaline phosphatase, as an enzyme marking epithelial type II cells, following manufacturer's  
510 instructions (Alkaline phosphatase Kit, Sigma). The intensity of pink stain reflects the amount of  
511 alkaline phosphatase in positive cells.

512 **ACE2 immunohistochemical staining in human lung tissue sections**

513 Human lungs were maintained in 10% formalin for 24 hours and then embedded in paraffin.  
514 Paraffin-embedded lungs were cut into 4  $\mu$ m sections. After removing the paraffin, endogenous  
515 peroxidases were inactivated in an aqueous solution containing 3% H<sub>2</sub>O<sub>2</sub> and 10% methanol and  
516 antigen retrieval was performed heating the samples in citrate buffer (10mM citric acid, pH 6.0).

517 The sections were then blocked in bovine serum albumin (5%), incubated with anti-ACE2  
518 antibody (R&D Systems cat. nº AF933, dilution 1:100) and with biotinylated secondary antibody  
519 against goat IgGs (Vector Laboratories cat. nº BA-9500, dilution 1:250). Proteins were visualized  
520 using the ABC Peroxidase Standard Staining Kit (ThermoFisher) followed by 3,3'-  
521 Diaminobenzidine (DAB) Enhanced Liquid Substrate System (Sigma Aldrich). Counterstaining  
522 was done with hematoxylin.

523 **Antiviral screening assay**

524 The complete list of compounds tested in this study, including information about its clinical  
525 use, product reference and vendors is shown in **Table S1**. Duplicates of five-fold serial dilutions  
526 of 39 antiviral compounds were tested in both VeroE6 cell line and in human lung tissue (HLT)  
527 cells using at least 2 different donors. For VeroE6, five-fold serial dilutions of the compounds,  
528 ranging from 100 $\mu$ M to 0.25nM, were prepared in D10 in a 96-well flat-bottom plates. VeroE6  
529 cells were added at a density of 30.000 cells/well and incubated with the drug for at least 1 h  
530 before infection. Subsequently, cells were infected with 1,500 TCID<sub>50</sub> of VSV\* $\Delta$ G(Luc)-S virus. In  
531 parallel, drug cytotoxicity was monitored by luminescence. To evaluate the antiviral activity of  
532 drugs in HLT cells, five-fold serial dilutions of the compounds, ranging from 100 $\mu$ M to 0.8 $\mu$ M or  
533 6.4nM, were prepared in R10 in a 96-well conic-bottom plates. HLT cells were added at a density  
534 of 300,000 cells/well and incubated with the compound for at least 1h before infection. Then,  
535 MOI 0.1 of VSV\* $\Delta$ G(Luc)-S virus were added to wells, and plates were spinoculated at 1,200g  
536 and 37°C for 2h. After infection, fresh medium was added to the wells and cell suspensions were  
537 transferred into a 96-well flat-bottom plate. Cells were then cultured overnight at 37°C in a 5%  
538 CO<sub>2</sub> incubator. Each plate contained the following controls: no cells (background control), cells  
539 treated with medium (mock infection) and cells infected but untreated (infection control). After  
540 20h, cells were incubated with Britelite plus reagent (Britelite plus kit; PerkinElmer) and then  
541 transferred to an opaque black plate. Luminescence was immediately recorded by a  
542 luminescence plate reader (LUMIstar Omega). To evaluate cytotoxicity, we used the CellTiter-  
543 Glo® Luminescent kit (Promega), following the manufacturer's instructions. Data was  
544 normalized to the mock-infected control, after which EC<sub>50</sub> and CC<sub>50</sub> values were calculated using  
545 Graph-Pad Prism 7.

546 **Drug validation with replication competent SARS-CoV-2**

547 These experiments were performed in a BSL3 facility (Viral Vector Production Unit,  
548 Universitat Autònoma de Barcelona, UAB). The SARS-CoV-2 virus was isolated from a

549 nasopharyngeal swab from an infected patient hospitalized at the Vall d'Hebron Hospital.  
550 VeroE6 cells were cultured on a cell culture flask (25 cm<sup>2</sup>) at 1.5 × 10<sup>6</sup> cells overnight prior to  
551 inoculation with 1 mL of medium from a Deltaswab VICUM® tub containing the swab. Cells were  
552 cultured for 1h at 37°C and 5% CO<sub>2</sub>. Afterwards, DMEM containing 2% FCS were added to the  
553 cells and incubated for 48h. Cells were assessed daily for cytopathic effect and the supernatant  
554 was recollected and subjected to viral titration in VeroE6 by plaque assay.

555 For antiviral drug validation, HLT samples were incubated with different drugs at 20µM for  
556 at least 1h before infection. Tested drugs were camostat, cephalexin, ergoloid,  
557 hydroxychloroquine, ivermectin and ciclesonide. Then, cells were infected with a MOI 0.5 of the  
558 SARS-CoV-2 viral isolate, and the plate was incubated for 2h at 37°C and 5% CO<sub>2</sub>. After infection,  
559 samples were extensively washed with PBS 1X to eliminate residual virus and suspended in fresh  
560 media containing antiviral drugs and transferred into a new plate. 24 or 48h post infection, 140µl  
561 of supernatant was collected in tubes containing 140µl of DNA/RNA Shield (Zymo Research) for  
562 SARS-CoV-2 inactivation. For each experiment, a negative control, cells treated with only  
563 medium, and a positive control, cells incubated in the presence of the virus alone, were included.  
564 Percentage of viral infection was calculated by RT-PCR. Briefly, viral RNA from the supernatant  
565 was extracted using the QIAamp Viral RNA Mini Kit (Qiagen), following the manufacturer's  
566 instructions. RNA was reverse transcribed with SuperScript III (Invitrogen), in accordance with  
567 the instructions provided by the manufacturer, and cDNA was quantified by qPCR using the  
568 2019-nCoV CDC RUO Kit (IDT, catalog #10006713) for the detection of viral RNA of the  
569 nucleocapsid region N1 from the SARS-CoV-2 (N1 forward 5'-GACCCCAAAATCAGCGAAAT-3' and  
570 N1 reverse 5'-TCTGGTTACTGCCAGTTGAATCTG-3'; N1 probe 5'-FAMACCCCGCAT/ZEN/TACGTTT  
571 GGTGGACC-3IABkFQ-3'). Copies of SARS-CoV-2 RNA were quantified using a standard (2019-  
572 nCoV\_N\_Positive Control from IDT, catalog #10006625). Samples were run on a 7000 SDS  
573 instrument (Applied Biosystems).

574 **Modulation of ACE2 expression by anti-inflammatory drugs and immune stimuli**

575 VeroE6 and lung cells were incubated with five-fold serial dilutions of selected anti-  
576 inflammatory compounds (ranging from 100µM to 0.8µM) for 20h. Tested drugs included  
577 cortisol, ibuprofen, prednisone and dexamethasone. Lung cells were also incubated with the  
578 following cytokines: GM-CSF (100 ng/ml, Immunotools), IL-1β (10 ng/ml, Immunotools), IL-10  
579 (100 ng/ml, Immunotools), IFN-β (100 U/ml, Immunotools), or IFN-α2 (100 U/ml, Sigma Aldrich).  
580 For determination of ACE2 expression, the following surface staining antibodies were used:  
581 primary goat anti-ACE2 (R&D Systems), anti-CD45 (AF700, BioLegend), anti-EpCAM (APC,

582 BioLegend), and anti-HLA-DR (BV421, BioLegend). For ACE2 detection, cells were then stained  
583 with secondary donkey anti-goat IgG (PE, R&D Systems) for 30 min at 4 °C. A Fluorescent Minus  
584 One control (FMO) without primary anti-ACE2 antibody was used as a control. Cell viability was  
585 determined using an AQUA viability dye for flow cytometry (LIVE/DEAD fixable AQUA,  
586 Invitrogen). After fixation with PBS 2% PFA, cells were acquired in an LSR Fortessa (BD  
587 Biosciences) and analyzed using the FlowJo v10.6.1 software (TreeStar).

588 **Immunomodulatory capacity of selected drugs**

589 HLT cells were cultured in a round-bottom 96-well plate containing 20 µM of cepharanthine,  
590 ergoloid, ciclesonide, hydroxychloroquine, ivermectin, or camostat mesylate alone or in  
591 combination with the stimuli LPS (50 ng/ml) and IFN-γ (100 ng/ml). For each patient, a negative  
592 control, cells treated with only medium, and a positive control, cells incubated in the presence  
593 of LPS and IFN-γ, were included. Immediately, brefeldin A (BD Biosciences) and monensin (BD  
594 Biosciences) were added to cells and cultured overnight at 37 °C in 5% CO<sub>2</sub>. Next day, cellular  
595 suspensions were stained with the following antibodies: anti-CD11b (FITC, BioLegend), anti-  
596 CD69 (PE-CF594, BD Biosciences), anti-CD14 (APC-H7, BD Biosciences), anti-EpCAM (APC,  
597 BioLegend), anti-CD3 (BV650, BD Biosciences), anti-CD45 (BV605, BioLegend), and anti-HLA-DR  
598 (BV421, BioLegend). Cells were subsequently fixed and permeabilized using the  
599 Cytofix/Cytoperm™ kit (BD Biosciences) and intracellularly stained with anti-IL-6 (PE-Cy7,  
600 BioLegend), and anti-CXCL10 (PE, BioLegend). Cell viability was determined using an AQUA  
601 viability dye for flow cytometry (LIVE/DEAD fixable AQUA, Invitrogen). After fixation with PBS  
602 2% PFA, cells were acquired in an LSR Fortessa (BD Biosciences), and data were analyzed using  
603 the FlowJo v10.6.1 software (TreeStar).

604 **Statistical analyses**

605 Statistical analyses were performed with Prism software, version 6.0 (GraphPad). A P value  
606 <0.05 was considered significant.

607 **Author contributions**

608 Conceptualization, MJ.B. and M.G.; Sample Collection, J.R.; Methodology J.G-E, D.P, M.S, N.  
609 M, A.V, MJ.S, J.G-P, J.A, J.B, B.T, A.S.M and V.F; Formal Analysis, J.G-E., D.P, M.S, M.G and MJ.B;  
610 Writing-Original Draft J.G-E and MJ.B; Writing- Review & Editing, J.G-E, M.G. and MJ.B; Funding  
611 Acquisition, M.G and MJ.B.; all authors revised the manuscript; Supervision, M.G and MJ.B.

612 **Acknowledgments**

613 This work was primarily supported by a grant from the Health Department of the  
614 Government of Catalonia (DGRIS 1\_5). This work was additionally supported in part by the  
615 Spanish Health Institute Carlos III (ISCIII, PI17/01470; PI19CIII/00004; PI21CIII/00025 and COV20-  
616 00679 (MPY 222-20)), the Spanish Secretariat of Science and Innovation and FEDER funds (grant  
617 RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish AIDS network Red Temática Cooperativa  
618 de Investigación en SIDA (RD16/0025/0007 and RD16CIII/0002/0001), the European Regional  
619 Development Fund (ERDF), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814-  
620 10FMTV3), the Gilead fellowships GLD19/00084 and GLD18/00008 and the Becas Taller Argal  
621 2020. M.J.B is supported by the Miguel Servet program funded by the Spanish Health Institute  
622 Carlos III (CP17/00179). N.M. is supported by a Ph.D. fellowship from the Vall d'Hebron Institut  
623 de Recerca (VHIR). The funders had no role in study design, data collection and analysis, the  
624 decision to publish, or preparation of the manuscript.

625      **References**

- 626      1. Goldman, J.D., et al., *Remdesivir for 5 or 10 Days in Patients with Severe Covid-19*. N Engl  
627      J Med, 2020. **383**(19): p. 1827-1837.
- 628      2. Beigel, J.H., et al., *Remdesivir for the Treatment of Covid-19 - Final Report*. N Engl J Med,  
629      2020. **383**(19): p. 1813-1826.
- 630      3. Cox, R.M., J.D. Wolf, and R.K. Plemper, *Therapeutically administered ribonucleoside*  
631      *analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets*. Nat Microbiol,  
632      2021. **6**(1): p. 11-18.
- 633      4. Painter, W.P., et al., *Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir,*  
634      *a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2*.  
635      Antimicrob Agents Chemother, 2021.
- 636      5. Group, R.C., et al., *Dexamethasone in Hospitalized Patients with Covid-19*. N Engl J Med,  
637      2021. **384**(8): p. 693-704.
- 638      6. Takayama, K., *In Vitro and Animal Models for SARS-CoV-2 research*. Trends Pharmacol  
639      Sci, 2020. **41**(8): p. 513-517.
- 640      7. Mossel, E.C., et al., *Exogenous ACE2 expression allows refractory cell lines to support*  
641      *severe acute respiratory syndrome coronavirus replication*. J Virol, 2005. **79**(6): p. 3846-  
642      50.
- 643      8. Ortiz, M.E., et al., *Heterogeneous expression of the SARS-CoV-2 receptor ACE2 in*  
644      *the human respiratory tract*. EBioMedicine, 2020. **60**: p. 102976.
- 645      9. Hou, Y.J., et al., *SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in*  
646      *the Respiratory Tract*. Cell, 2020. **182**(2): p. 429-446 e14.
- 647      10. Koch, J., et al., *Host Cell Proteases Drive Early or Late SARS-CoV-2 Penetration*. bioRxiv,  
648      2020.
- 649      11. Hoffmann, M., et al., *SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is*  
650      *Blocked by a Clinically Proven Protease Inhibitor*. Cell, 2020. **181**(2): p. 271-280 e8.
- 651      12. Ziegler, C.G.K., et al., *SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in*  
652      *Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues*. Cell,  
653      2020. **181**(5): p. 1016-1035 e19.
- 654      13. Qiao, W., et al., *Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic*  
655      *rats*. Cardiology, 2015. **131**(2): p. 97-106.
- 656      14. Moore, N., et al., *Does Ibuprofen Worsen COVID-19?* Drug Saf, 2020. **43**(7): p. 611-614.
- 657      15. Kutti Sridharan, G., et al., *COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?*  
658      Am J Ther, 2020. **27**(4): p. e400-e402.
- 659      16. Xiang, Z., et al., *Glucocorticoids improve severe or critical COVID-19 by activating ACE2*  
660      *and reducing IL-6 levels*. Int J Biol Sci, 2020. **16**(13): p. 2382-2391.
- 661      17. Ravindra, N.G., et al., *Single-cell longitudinal analysis of SARS-CoV-2 infection in human*  
662      *airway epithelium identifies target cells, alterations in gene expression, and cell state*  
663      *changes*. PLoS Biol, 2021. **19**(3): p. e3001143.
- 664      18. Si, L., et al., *A human-airway-on-a-chip for the rapid identification of candidate antiviral*  
665      *therapeutics and prophylactics*. Nat Biomed Eng, 2021.
- 666      19. Blanco-Melo, D., et al., *Imbalanced Host Response to SARS-CoV-2 Drives Development*  
667      *of COVID-19*. Cell, 2020. **181**(5): p. 1036-1045 e9.
- 668      20. Lamers, M.M., et al., *An organoid-derived bronchioalveolar model for SARS-CoV-2*  
669      *infection of human alveolar type II-like cells*. EMBO J, 2021. **40**(5): p. e105912.
- 670      21. Kim, J., B.K. Koo, and J.A. Knoblich, *Human organoids: model systems for human biology*  
671      *and medicine*. Nat Rev Mol Cell Biol, 2020. **21**(10): p. 571-584.
- 672      22. Chang, Y., et al., *Upregulation of IL-17A/F from human lung tissue explants with cigarette*  
673      *smoke exposure: implications for COPD*. Respir Res, 2014. **15**: p. 145.

674 23. Hackett, T.L., et al., *Oxidative modification of albumin in the parenchymal lung tissue of*  
675 *current smokers with chronic obstructive pulmonary disease.* *Respir Res*, 2010. **11**: p. 180.

677 24. Rimington, T.L., et al., *Defining the inflammatory signature of human lung explant tissue*  
678 *in the presence and absence of glucocorticoid.* *F1000Res*, 2017. **6**: p. 460.

679 25. Schaller, M.A., et al., *In vitro infection of human lung tissue with SARS-CoV-2: Heterogeneity in host defense and therapeutic response.* *bioRxiv*, 2021: p. 2021.01.20.427541.

682 26. Hasegawa, K., et al., *Fraction of MHCII and EpCAM expression characterizes distal lung*  
683 *epithelial cells for alveolar type 2 cell isolation.* *Respir Res*, 2017. **18**(1): p. 150.

684 27. Wosen, J.E., et al., *Epithelial MHC Class II Expression and Its Role in Antigen Presentation*  
685 *in the Gastrointestinal and Respiratory Tracts.* *Front Immunol*, 2018. **9**: p. 2144.

686 28. Singer, B.D., et al., *Flow-cytometric method for simultaneous analysis of mouse lung*  
687 *epithelial, endothelial, and hematopoietic lineage cells.* *Am J Physiol Lung Cell Mol*  
688 *Physiol*, 2016. **310**(9): p. L796-801.

689 29. Baharom, F., et al., *Human Lung Mononuclear Phagocytes in Health and Disease.* *Front*  
690 *Immunol*, 2017. **8**: p. 499.

691 30. Katsumiti, A., et al., *Immortalisation of primary human alveolar epithelial lung cells using*  
692 *a non-viral vector to study respiratory bioreactivity in vitro.* *Sci Rep*, 2020. **10**(1): p. 20486.

694 31. Stephan W. Glasser, J.E.B., Thomas R. Korfhagen, *Surfactant Protein-C in the*  
695 *Maintenance of Lung Integrity and Function.* *J Aller Ther*, 2011. **S7**(001).

696 32. Beers, M.F. and Y. Moodley, *When Is an Alveolar Type 2 Cell an Alveolar Type 2 Cell? A*  
697 *Conundrum for Lung Stem Cell Biology and Regenerative Medicine.* *Am J Respir Cell Mol*  
698 *Biol*, 2017. **57**(1): p. 18-27.

699 33. Qi, F., et al., *Single cell RNA sequencing of 13 human tissues identify cell types and*  
700 *receptors of human coronaviruses.* *Biochem Biophys Res Commun*, 2020. **526**(1): p. 135-140.

702 34. Wang, K., et al., *CD147-spike protein is a novel route for SARS-CoV-2 infection to host*  
703 *cells.* *Signal Transduct Target Ther*, 2020. **5**(1): p. 283.

704 35. Qi, J., et al., *The scRNA-seq Expression Profiling of the Receptor ACE2 and the Cellular*  
705 *Protease TMPRSS2 Reveals Human Organs Susceptible to SARS-CoV-2 Infection.* *Int J*  
706 *Environ Res Public Health*, 2021. **18**(1).

707 36. Lukassen, S., et al., *SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in*  
708 *bronchial transient secretory cells.* *EMBO J*, 2020. **39**(10): p. e105114.

709 37. Wang, S., et al., *AXL is a candidate receptor for SARS-CoV-2 that promotes infection of*  
710 *pulmonary and bronchial epithelial cells.* *Cell Res*, 2021. **31**(2): p. 126-140.

711 38. Condor Capcha, J.M., et al., *Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral*  
712 *Entry and Neutralization Assays: A 1-Week Protocol.* *Front Cardiovasc Med*, 2020. **7**: p. 618651.

714 39. Fukushi, S., et al., *Vesicular stomatitis virus pseudotyped with severe acute respiratory*  
715 *syndrome coronavirus spike protein.* *J Gen Virol*, 2005. **86**(Pt 8): p. 2269-2274.

716 40. Kuba, K., et al., *A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS*  
717 *coronavirus-induced lung injury.* *Nat Med*, 2005. **11**(8): p. 875-9.

718 41. Ou, X., et al., *Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its*  
719 *immune cross-reactivity with SARS-CoV.* *Nat Commun*, 2020. **11**(1): p. 1620.

720 42. Smith, M. and J.C. Smith, *Repurposing Therapeutics for COVID-19: Supercomputer-Based*  
721 *Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2*  
722 *Interface.* *ChemRxiv*, 2020.

723 43. Suffness, M. and J. Pezzuto, *Methods in plant biochemistry: assays for bioactivity.*  
724 Academic Press, London, 1990: p. 71-133.

725 44. Yao, X., et al., *In Vitro Antiviral Activity and Projection of Optimized Dosing Design of*  
726 *Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome*  
727 *Coronavirus 2 (SARS-CoV-2)*. *Clin Infect Dis*, 2020. **71**(15): p. 732-739.

728 45. Maisonnasse, P., et al., *Hydroxychloroquine use against SARS-CoV-2 infection in non-*  
729 *human primates*. *Nature*, 2020. **585**(7826): p. 584-587.

730 46. Alméciga-Díaz, C.J., et al., *Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main*  
731 *Protease*. 2020, *Preprints.org*.

732 47. Hoffmann, M., et al., *Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-*  
733 *related proteases and its metabolite GBPA exerts antiviral activity*. *EBioMedicine*, 2021.  
734 **65**: p. 103255.

735 48. Gunst, J.D., et al., *Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients*  
736 *hospitalized with Covid-19-a double-blind randomized controlled trial*. *EClinicalMedicine*, 2021. **35**: p. 100849.

738 49. Lehrer, S., *Inhaled biguanides and mTOR inhibition for influenza and coronavirus*  
739 *(Review)*. *World Acad Sci J*, 2020. **2**(3).

740 50. Islam, A., et al., *The pharmacological and biological roles of eriodictyol*. *Arch Pharm Res*,  
741 2020. **43**(6): p. 582-592.

742 51. Hempel, T., et al., *Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator*  
743 *TMPRSS2 with camostat and nafamostat*. *Chemical Science*, 2021. **12**(3): p. 983-992.

744 52. Su, S. and S. Jiang, *A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by*  
745 *enhancing expression of ACE2*. *Signal Transduct Target Ther*, 2020. **5**(1): p. 71.

746 53. Vabret, N., et al., *Immunology of COVID-19: Current State of the Science*. *Immunity*,  
747 2020. **52**(6): p. 910-941.

748 54. Smart, L., et al., *A narrative review of the potential pharmacological influence and safety*  
749 *of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a*  
750 *dichotomy of expectation and reality*. *Inflammopharmacology*, 2020. **28**(5): p. 1141-  
751 1152.

752 55. Grau-Exposito, J., et al., *Peripheral and lung resident memory T cell responses against*  
753 *SARS-CoV-2*. *Nat Commun*, 2021. **12**(1): p. 3010.

754 56. Hamming, I., et al., *Tissue distribution of ACE2 protein, the functional receptor for SARS*  
755 *coronavirus. A first step in understanding SARS pathogenesis*. *J Pathol*, 2004. **203**(2): p.  
756 631-7.

757 57. Shang, J., et al., *Cell entry mechanisms of SARS-CoV-2*. *Proc Natl Acad Sci U S A*, 2020.  
758 **117**(21): p. 11727-11734.

759 58. Valyaeva, A.A., et al., *Expression of SARS-CoV-2 entry factors in lung epithelial stem cells*  
760 *and its potential implications for COVID-19*. *Sci Rep*, 2020. **10**(1): p. 17772.

761 59. Kaufer, A.M., et al., *Laboratory biosafety measures involving SARS-CoV-2 and the*  
762 *classification as a Risk Group 3 biological agent*. *Pathology*, 2020. **52**(7): p. 790-795.

763 60. Walls, A.C., et al., *Structure, Function, and Antigenicity of the SARS-CoV-2 Spike*  
764 *Glycoprotein*. *Cell*, 2020. **183**(6): p. 1735.

765 61. Ogando, N.S., et al., *SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics,*  
766 *rapid adaptation and cytopathology*. *J Gen Virol*, 2020. **101**(9): p. 925-940.

767 62. Jeon, S., et al., *Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-*  
768 *Approved Drugs*. *Antimicrob Agents Chemother*, 2020. **64**(7).

769 63. Rogosnitzky, M., P. Okediji, and I. Koman, *Cepharanthine: a review of the antiviral*  
770 *potential of a Japanese-approved alopecia drug in COVID-19*. *Pharmacol Rep*, 2020.  
771 **72**(6): p. 1509-1516.

772 64. Hoffmann, M., et al., *Chloroquine does not inhibit infection of human lung cells with*  
773 *SARS-CoV-2*. *Nature*, 2020. **585**(7826): p. 588-590.

774 65. Omrani, A.S., et al., *Randomized double-blinded placebo-controlled trial of*  
775 *hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-*  
776 *19*. *EClinicalMedicine*, 2020. **29**: p. 100645.

777 66. Boulware, D.R., et al., *A Randomized Trial of Hydroxychloroquine as Postexposure*  
778 *Prophylaxis for Covid-19*. *N Engl J Med*, 2020. **383**(6): p. 517-525.

779 67. Mitja, O., et al., *Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A*  
780 *Randomized-Controlled Trial*. *Clin Infect Dis*, 2020.

781 68. Ou, T., et al., *Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated*  
782 *by TMPRSS2*. *PLoS Pathog*, 2021. **17**(1): p. e1009212.

783 69. Mulay, A., et al., *SARS-CoV-2 infection of primary human lung epithelium for COVID-19*  
784 *modeling and drug discovery*. *Cell Rep*, 2021. **35**(5): p. 109055.

785 70. Satarker, S., et al., *Hydroxychloroquine in COVID-19: Potential Mechanism of Action*  
786 *Against SARS-CoV-2*. *Curr Pharmacol Rep*, 2020: p. 1-9.

787 71. Bray, M., et al., *Ivermectin and COVID-19: A report in Antiviral Research, widespread*  
788 *interest, an FDA warning, two letters to the editor and the authors' responses*. *Antiviral*  
789 *Res*, 2020. **178**: p. 104805.

790 72. Chacour, C., et al., *The effect of early treatment with ivermectin on viral load, symptoms*  
791 *and humoral response in patients with non-severe COVID-19: A pilot, double-blind,*  
792 *placebo-controlled, randomized clinical trial*. *EClinicalMedicine*, 2021. **32**: p. 100720.

793 73. Onabajo, O.O., et al., *Interferons and viruses induce a novel truncated ACE2 isoform and*  
794 *not the full-length SARS-CoV-2 receptor*. *Nat Genet*, 2020. **52**(12): p. 1283-1293.

795 74. Ng, K.W., et al., *Tissue-specific and interferon-inducible expression of nonfunctional*  
796 *ACE2 through endogenous retroelement co-option*. *Nat Genet*, 2020. **52**(12): p. 1294-  
797 1302.

798 75. Busnadio, I., et al., *Antiviral Activity of Type I, II, and III Interferons Counterbalances*  
799 *ACE2 Inducibility and Restricts SARS-CoV-2*. *mBio*, 2020. **11**(5).

800 76. de Lang, A., A.D. Osterhaus, and B.L. Haagmans, *Interferon-gamma and interleukin-4*  
801 *downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells*.  
802 *Virology*, 2006. **353**(2): p. 474-81.

803 77. Russell, A.B., C. Trapnell, and J.D. Bloom, *Extreme heterogeneity of influenza virus*  
804 *infection in single cells*. *Elife*, 2018. **7**.

805 78. Hall, K.C. and C.P. Blobel, *Interleukin-1 stimulates ADAM17 through a mechanism*  
806 *independent of its cytoplasmic domain or phosphorylation at threonine 735*. *PLoS One*,  
807 2012. **7**(2): p. e31600.

808 79. Heurich, A., et al., *TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis*  
809 *by TMPRSS2 augments entry driven by the severe acute respiratory syndrome*  
810 *coronavirus spike protein*. *J Virol*, 2014. **88**(2): p. 1293-307.

811 80. Domingo, P., et al., *The four horsemen of a viral Apocalypse: The pathogenesis of SARS-*  
812 *CoV-2 infection (COVID-19)*. *EBioMedicine*, 2020. **58**: p. 102887.

813 81. Fraga-Silva, R.A., et al., *The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas*  
814 *receptor axis: a potential target for treating thrombotic diseases*. *Thromb Haemost*,  
815 2012. **108**(6): p. 1089-96.

816 82. Cavalli, G., et al., *Interleukin-1 and interleukin-6 inhibition compared with standard*  
817 *management in patients with COVID-19 and hyperinflammation: a cohort study*. *Lancet*  
818 *Rheumatol*, 2021. **3**(4): p. e253-e261.

819 83. Liao, M., et al., *Single-cell landscape of bronchoalveolar immune cells in patients with*  
820 *COVID-19*. *Nat Med*, 2020. **26**(6): p. 842-844.

821 84. Chen, J.S., et al., *Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and*  
822 *Antibody Response to SARS-CoV-2 Infection*. *Journal of Virology*, 2021. **95**(7): p. e00014-  
823 21.

824 85. Zhang, D., et al., *Frontline Science: COVID-19 infection induces readily detectable*  
825 *morphologic and inflammation-related phenotypic changes in peripheral blood*  
826 *monocytes*. *J Leukoc Biol*, 2021. **109**(1): p. 13-22.

827 86. Fahlberg, M.D., et al., *Cellular events of acute, resolving or progressive COVID-19 in*  
828 *SARS-CoV-2 infected non-human primates*. *Nat Commun*, 2020. **11**(1): p. 6078.

829 87. Aggarwal, N.R., L.S. King, and F.R. D'Alessio, *Diverse macrophage populations mediate*  
830 *acute lung inflammation and resolution*. Am J Physiol Lung Cell Mol Physiol, 2014.  
831 **306**(8): p. L709-25.

832 88. Yamaya, M., et al., *The serine protease inhibitor camostat inhibits influenza virus*  
833 *replication and cytokine production in primary cultures of human tracheal epithelial*  
834 *cells*. Pulm Pharmacol Ther, 2015. **33**: p. 66-74.

835 89. Zhang, X., et al., *Ivermectin inhibits LPS-induced production of inflammatory cytokines*  
836 *and improves LPS-induced survival in mice*. Inflamm Res, 2008. **57**(11): p. 524-9.

837 90. Whitt, M.A., *Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies*  
838 *on virus entry, identification of entry inhibitors, and immune responses to vaccines*. J  
839 Virol Methods, 2010. **169**(2): p. 365-74.

840 91. Li, M., et al., *Human immunodeficiency virus type 1 env clones from acute and early*  
841 *subtype B infections for standardized assessments of vaccine-elicited neutralizing*  
842 *antibodies*. J Virol, 2005. **79**(16): p. 10108-25.

843

844 **Figure legends**

845 **Figure 1. Phenotyping of human lung cells.** (A). *t*-distributed Stochastic Neighbor  
846 Embedding (t-SNE) representation displaying the major cell clusters present in the CD45<sup>+</sup> and  
847 CD45<sup>-</sup> EpCAM<sup>+</sup> fractions of a representative human lung tissue. The vertical bars in the right  
848 panel show the frequency of each subset relative to live cells. All cell subsets were identified as  
849 shown in Figure S1A. mDCs, myeloid dendritic cells; enriched AT-II, enriched fraction in alveolar  
850 type 2. (B). Phosphatase alkaline positive AT-II cells (pink staining) were detected in a cytopsin  
851 obtained from human lung tissue cells and observed at 10x. Lower panel shows a high  
852 magnification (40x) of the black square. Scale bars are 100  $\mu$ m and 10  $\mu$ m in top and bottom  
853 panels, respectively. (C). *t*-distributed Stochastic Neighbor Embedding (tSNE) representation for  
854 ACE2, CD147 and TMPRSS2 expression in CD45<sup>+</sup> and CD45<sup>-</sup>EpCAM<sup>+</sup> fractions from a  
855 representative lung tissue. Right graphs show the percentage of expression of each entry factor  
856 in the different cell subpopulations, which were identified as in Figure 1A with some  
857 modifications for the identification of myeloid cells and neutrophils (From big cells:  
858 monocytes/macrophages, CD11c<sup>+</sup>HLA-DR<sup>+</sup>CD14<sup>+</sup>; Alveolar macrophages and mDCs, CD11c<sup>+</sup>HLA-  
859 DR<sup>+</sup>CD14<sup>-</sup>; Neutrophils, CD11c<sup>-</sup>HLA-DR<sup>-</sup>CD14<sup>-</sup>CD3<sup>+</sup>). (D). Images of ACE2 immunohistochemical  
860 staining in human lung tissue sections at 40x magnification, counterstained with haematoxylin  
861 (top) or without (bottom). Black arrows indicate staining of ACE2 in AT-II cells (upper panel).  
862 Mean $\pm$ SEM is shown for all graphs.

863 **Figure 2. Susceptibility of VeroE6 and the HLT model to SARS-CoV-2 viral entry.** VeroE6 and  
864 HLT cells were infected with two different viral constructs (GFP and Luciferase) expressing the  
865 spike protein upon viral entry; VSV\* $\Delta$ G(GFP)-Spike and VSV\* $\Delta$ G(Luc)-Spike. (A) Representative  
866 flow cytometry plots of VeroE6 cells infected with VSV\* $\Delta$ G(GFP)-Spike or the background form  
867 VSV\* $\Delta$ G(GFP)-empty (left panel); and luciferase activity (RLUs; relative light units) at 20h post-  
868 infection with the pseudotyped VSV\*G(Luc)-G, the VSV\* $\Delta$ G(Luc)-Spike or the background form  
869 VSV\* $\Delta$ G(Luc)-empty (right panel). (B) Percentage of viral entry after treatment with anti-ACE2  
870 antibody (10 $\mu$ g/ml) and camostat (100 $\mu$ M) in VeroE6 cells infected with the pseudotyped virus  
871 expressing the control G protein or the spike from SARS-CoV-2. (C) A flow cytometry plot  
872 showing ACE2 expression in GFP<sup>+</sup> VeroE6 cells. Right graph shows mean fluorescence intensity  
873 (MFI) of ACE2 in both infected and uninfected fractions, based on GFP expression. (D)  
874 Representative flow cytometry plots of HLT cells infected with the viral construct expressing the  
875 spike protein (VSV\* $\Delta$ G(GFP)-Spike) or the background form (VSV\* $\Delta$ G(GFP)-empty) (left panel);  
876 and luciferase activity (RLUs; relative light units) at 20h post-infection with the VSV\* $\Delta$ G(Luc)-  
877 Spike or the background form VSV\* $\Delta$ G(Luc)-empty (right panel). Infection was measured as the

878 percentage of GFP or RLU, respectively. (E) Susceptible HLT cells to viral entry (identified as  
879 GFP<sup>+</sup> cells) compatible with an AT-II phenotype, determined by the co-expression of HLA-DR and  
880 EpCAM in the CD45 CD31<sup>+</sup> fraction of live cells. (F) Bar plots showing the percentage of viral entry  
881 inhibition on HLT cells in the presence of anti-ACE2 antibody (15 $\mu$ g/ml), camostat (100 $\mu$ M) or  
882 anti-CD147 antibody (25 $\mu$ g/ml) after cell challenge with VSV\* $\Delta$ G(Luc)-Spike (left graph) or  
883 VSV\* $\Delta$ G(GFP)-Spike (right graph). Mean $\pm$ SEM is shown for all graphs. Data in panel 2C were  
884 analyzed by a Wilcoxon matched-pairs test; \*p<0.05. Data in panel 2F were analyzed by one  
885 sample t-test; \*p<0.05, \*\*p<0.01, \*\*\*p<0.0001

886 **Figure 3. Antiviral assays with concordant results between models.** (A). Percentage of viral  
887 entry in VeroE6 and HLT cells exposed to VSV\* $\Delta$ G(Luc)-Spike in the presence of cepharanthine,  
888 ergoloid, hydroxychloroquine, hypericin, licoferol, ivermectin, ciclesonide, quercetin,  
889 vidarabine and celecoxib. Drugs were used at concentrations ranging from 100 $\mu$ M to 0.256nM,  
890 in VeroE6, and to 0.8 $\mu$ M in lung cells. Non-linear fit model with variable response curve from at  
891 least three independent experiments in replicates is shown (red lines). Cytotoxic effect on  
892 VeroE6 cells and HLT exposed to drug concentrations in the absence of virus is also shown (green  
893 lines). (B). EC<sub>50</sub> values of each drug in VeroE6 and HLT cells. (C). CC<sub>50</sub> values of each drug are  
894 shown for VeroE6 and for HLT cells.

895 **Figure 4. Antiviral assays with discordant results between models.** (A). Percentage of viral  
896 entry in VeroE6 and HLT cells exposed to VSV\* $\Delta$ G(Luc)-Spike in the presence of luteolin,  
897 eriodictyol, phenformin, camostat, sulindac, and valaciclovir. Drugs were used at concentrations  
898 ranging from 100 $\mu$ M to 0.256 nM, in VeroE6, and to 0.8 $\mu$ M in lung cells. Non-linear fit model  
899 with variable response curve from at least three independent experiments in replicates is shown  
900 (red lines). Cytotoxic effect on VeroE6 cells and HLT exposed to drug concentrations in the  
901 absence of virus is also shown (green lines). (B). EC<sub>50</sub> values of each drug in VeroE6 and HLT cells.  
902 (C). CC<sub>50</sub> values of each drug are shown for VeroE6 and HLT cells. (D). Percentage of viral entry  
903 in HLT cells exposed to VSV\* $\Delta$ G(Luc)-Spike-delta and VSV\* $\Delta$ G(Luc)-Spike-D614G variants in the  
904 presence of ivermectin, camostat, hydroxychloroquine, cepharanthine and ciclesonide. Drugs  
905 were used at concentrations ranging from 100 $\mu$ M to 0.8 $\mu$ M. (E) Number of viral genomes/ $\mu$ l at  
906 24h and 48h after infection with replication-competent SARS-CoV-2. (F). Percentage of viral  
907 replication in the presence of 20 $\mu$ M of camostat, cepharanthine, hydroxychloroquine,  
908 ivermectin and ciclesonide after infection with replication-competent SARS-CoV-2. Mean $\pm$ SEM  
909 is shown. Data in panel 4F were analyzed by one sample t-test; \*p<0.05, \*\*p<0.01.

910        **Figure 5. Impact of inflammation and anti-inflammatory drugs on SARS-CoV-2 viral entry**  
911        **and ACE2 expression.** Both models, HLT cells and VeroE6 cells, were incubated in the presence  
912        of different anti-inflammatory drugs to evaluate the modulation of ACE2 expression by flow  
913        cytometry and the antiviral effect by luminescence. **(A)** HLT cells were treated with different  
914        stimuli for 20h and the percentage of protein expression (left) or the mean fluorescence  
915        intensity (MFI, right) of ACE2 receptor was evaluated in the enriched AT-II fraction by flow  
916        cytometry. **(B)** Modulation of ACE2 protein expression was assessed by flow cytometry in both  
917        models, Vero E6 and HLT cells, in the presence of different concentrations of each anti-  
918        inflammatory drug, ranging from 100 $\mu$ M to 0.8 $\mu$ M. Percentage of ACE2 expression was  
919        quantified in AT-II cells from at least six independent lung samples, and in VeroE6 cells from 2  
920        independent experiments. **(C)** Cytotoxic effect on Vero E6 and HLT cells exposed to  
921        VSV\* $\Delta$ G(Luc)-Spike in the presence of different concentrations of the anti-inflammatory drugs  
922        prednisone, cortisol, ibuprofen and dexamethasone. Drugs were used at a concentration  
923        ranging from 100 $\mu$ M to 0.256 nM, in VeroE6, and to 0.8 $\mu$ M in lung cells. Non-linear fit with  
924        variable response curve from at least two experiments in replicates is shown (red lines).  
925        Cytotoxic effect on Vero E6 cells and HLT cells exposed to different concentrations of drugs in  
926        the absence of virus is also shown (green lines). Mean $\pm$ SEM are shown and statistical  
927        comparisons with the control medium were performed using the Wilcoxon test. \*p<0.05.

928        **Figure 6. Anti-inflammatory effect of compounds with antiviral activity against SARS-CoV-2.** HLT cells were cultured in the presence of 20 $\mu$ M of cepharamthine, ergoloid mesylate,  
929        ciclesonide, hydroxychloroquine sulfate, ivermectin or camostat mesylate, alone or in  
930        combination with the stimuli LPS (50 ng/ml) and IFN- $\gamma$  (100 ng/ml). **(A)** t-distributed Stochastic  
931        Neighbor Embedding (t-SNE) representations displaying the major cell clusters present in live  
932        CD45 $^+$  myeloid gate, based on FSC and SSC, of a representative human lung tissue in baseline  
933        conditions and after stimulation with LPS and IFN- $\gamma$ . Two major subsets of myeloid cells are  
934        shown (CD11b $^+$  CD14 $^+$ , in blue-green, and CD11b $^+$  CD14 $^-$ , in orange). The expression of CXCL10  
935        and IL-6 among the different populations is shown in maroon and green, respectively. **(B)**  
936        Expression of CXCL10 and IL-6 was measured in HLT cells in response to stimuli in the presence  
937        of selected drugs in both myeloid subpopulations, CD11b $^+$  CD14 $^+$  (left panel) and CD11b $^+$  CD14 $^-$   
938        (right panel). HQ, hydroxychloroquine. Mean $\pm$ SEM are represented and statistical comparisons  
939        with the control medium were performed using the One sample t test. \*p<0.05, \*\*p<0.01.

941        **Figure S1. Gating strategy for the identification of cell subpopulations in the human lung**  
942        **tissue model.** **(A)** General gating strategy used to identify different cell subsets in lung samples.  
943        A gate based on FSC vs. SSC was followed by doublet and dead cells exclusion. From live CD45 $^-$

944 cells, endothelial cells (CD31<sup>+</sup>, purple) and epithelial cells (EpCAM<sup>+</sup>, grey) were gated, and within  
945 epithelial cells, AT-II cells (EpCAM<sup>+</sup> and HLA-DR<sup>+</sup>, pink) were identified. Out of live CD45<sup>+</sup> cells  
946 and based on FSC vs. SSC, we identified a lymphocyte population in which we distinguished  
947 between non-T lymphocytes (turquoise) and T cells (dark green) based on CD3 expression; and  
948 big cells, where we identified three major subsets based on their expression of CD11b and CD11c  
949 and, subsequently, CD14 and HLA-DR markers. We identified alveolar macrophages (blue),  
950 monocytes (violet), myeloid dendritic cells (mDCs, fuchsia) and neutrophils (orange). **(B)**  
951 Representative flow cytometry plots showing Surfactant Protein C (SPC) staining and its  
952 respective fluorescence minus one (FMO) control. **(C)** Representative flow cytometry plots  
953 showing ACE2 staining and its respective fluorescence minus one (FMO) control.

954 **Figure S2. Optimization of lung tissue enzymatic digestion visualized by t-distributed**  
955 **Stochastic Neighbor Embedding (tSNE).** **(A)** Representative tSNE maps showing concatenated  
956 flow cytometry standard files for three different protocols based on different digestion enzymes  
957 (collagenase, liberase or trypsin) from total live cells (upper), CD45<sup>+</sup> cells (middle) and CD45<sup>-</sup> cells  
958 (lower). **(B)** Bar plots showing cell-type composition (count) analyzed by flow cytometry for each  
959 tissue protocol.

960 **Figure S3. (A)** t-distributed Stochastic Neighbor Embedding (tSNE) representation for AXL  
961 expression in CD45<sup>+</sup> and CD45<sup>-</sup>EpCAM<sup>+</sup> fractions from a representative lung tissue. Right graphs  
962 show the percentage of expression of the AXL entry factor in the different cell populations,  
963 which were identified as in Figure 1A. **(B)** Percentage of enriched AT-II cells co-expressing the  
964 entry factors ACE and CD147 (in blue), and ACE and TMPRSS2 (in purple). **(C)** Frequency of each  
965 subset relative to live cells at 0h and 24h with and without the presence of virus. All cell subsets  
966 were identified as shown in Figure S1A. **(D)** Bar plots showing the percentage of viral entry  
967 inhibition on HLT cells in the presence of anti-ACE2 antibody (15 $\mu$ g/ml) or recombinant human  
968 AXL (50 $\mu$ g/ml) after cell challenge with VSV\* $\Delta$ G(Luc)-Spike. Data were analyzed by one sample  
969 t-test; \*p<0.05, \*\*p<0.01. **(E)** EC<sub>50</sub> values for in the HLT model obtained from 3 different lung  
970 donors and performed in replicates. **(F)** Cells from 1 donor were cultured with 20  $\mu$ M of selected  
971 drugs for 48h, and cell toxicity was measured using the CellTiter-Glo<sup>®</sup> Luminescent kit  
972 (Promega), following the manufacturer's instructions. Data was normalized to the untreated  
973 control. Mean $\pm$ SEM is shown for all graphs.



974 **Figure S4. Gating strategy for the identification of anti-inflammatory effects of selected**  
975 **compounds.** General gating strategy used to evaluate the expression of inflammatory molecules  
976 in lung samples. A gate based on FSC vs. SSC was followed by doublet and dead cells exclusion.

977 From live CD45<sup>+</sup> cells and based on FSC vs. SSC, we identified lymphocyte population and big  
978 cells, in which we identified two subsets based on their expression of CD11b and CD14: myeloid  
979 CD11b<sup>+</sup>CD14<sup>+</sup> cells (blue-green) and myeloid CD11b<sup>+</sup>CD14<sup>-</sup> cells (orange) are shown.


980

Figure 1


A




B



C




D



ACE2

CD147


TMPRSS2




# Figure 2

## VeroE6


**A**



**B**




**C**




## HLT cells


**D**



**E**




**F**



# Figure 3

**A**



**B**


Drugs	VeroE6	HLT
	EC <sub>50</sub> (μM)	
Cepharanthine	0.46	6.08
Ergoloid	4.78	9.17
Hydroxychloroquine	1.58	3.22
Hypericin	1.24	0.31
Licofelone	87.50	32.16
Ivermectin	13.94	12.98
Ciclesonide	20.52	16.41
Luteolin	~70.7	~82.39
Vidarabine	>100	51.60
Celecoxib	12.99	55.72

**C**

Drugs	VeroE6	HLT
	CC <sub>50</sub> (μM)	
Cepharanthine	22.37	16.15
Ergoloid	18.67	~100
Hydroxychloroquine	>100	~100
Hypericin	4.80	0.14
Licofelone	>100	~53.61
Ivermectin	20.23	~100
Ciclesonide	>100	>100
Luteolin	>100	>100
Vidarabine	>100	>100
Celecoxib	12.98	~100

# Figure 4

A




B

Drugs	VeroE6	HLT
	$\text{EC}_{50}$ ( $\mu\text{M}$ )	
Camostat	no effect	3.30
Valaciclovir	no effect	>100
Phenformin	no effect	38.16
Eriodictyol	no effect	90
Quercetin	>100	no effect


C

Drugs	VeroE6	HLT
	$\text{CC}_{50}$ ( $\mu\text{M}$ )	
Camostat	>100	>100
Valaciclovir	>100	>100
Phenformin	>100	>100
Eriodictyol	>100	>100
Quercetin	>100	>100


D



E




F




# Figure 5


**A**




**B**



**C**



# Figure 6

**A****B**